Literature DB >> 11979090

Pleomorphic liposarcoma: clinicopathologic, immunohistochemical, and follow-up analysis of 63 cases: a study from the French Federation of Cancer Centers Sarcoma Group.

Sandra Gebhard1, Jean-Michel Coindre, Jean-Jacques Michels, Philippe Terrier, Gérard Bertrand, Martine Trassard, Sophia Taylor, Marie-Christine Château, Bernard Marquès, Véronique Picot, Louis Guillou.   

Abstract

The clinicopathologic and immunohistochemical features of 63 pleomorphic liposarcomas are presented. There were 35 men and 28 women (median age 63 years; range 18-93 years). Tumor size ranged from 2 to 23 cm (median 10 cm). Tumor locations included lower extremity (36.5%), especially the thigh (28.5%), limb girdles (17.5%), upper extremity (16%), thoracoabdominal wall (9.5%), and internal trunk (20.5%). A total of 75% were deep seated and/or extracompartmental. Histologically, lesions show a varying combination of lipogenic and nonlipogenic areas characterized by malignant fibrous histiocytoma-like, round cell liposarcoma-like, and/or epithelioid/carcinoma-like features. A pericytic pattern was focally present in 15 (24%) tumors. Eighteen (29%) lesions were grade 2, and 45 (71%) were grade 3 sarcomas. Tumor necrosis was observed in 51 (81%) cases, vascular invasion in three, and mitotic counts ranged from 3 to 124 per 10 high power fields (median 25). Lipogenic areas were S-100 protein immunoreactive, at least focally, in 20 of 42 (48%) cases. Nonlipogenic areas showed focal reactivity for smooth muscle actin (24 of 49; 49%), desmin (9 of 48; 19%), CD34 (18 of 45; 40%), S-100 protein (5 of 49, 10%), CD68 (6 of 46, 13%), and epithelial membrane antigen (13 of 49, 26.5%). Epithelioid areas showed epithelial membrane antigen (4 of 11; 36%) but not cytokeratin (0 of 11) reactivity. Treatment procedures in 51 patients consisted of simple tumorectomy (16) and wide excision (33). Five and 31 patients received neoadjuvant and adjuvant chemotherapy and/or radiation therapy, respectively. Follow-up (48 patients, range 7-276 months; median 38 months) showed a 45% local recurrence rate and a 42.5% metastasis rate, metastases occurring mostly in lungs and pleura. Seventeen patients (35%) died of disease, of whom none was metastatic at diagnosis. Five-year overall, metastasis-free, and local recurrence-free survivals were 57%, 50%, and 48%, respectively. Patient age > or =60 years, truncal tumor location, deep situation, tumor size >5 cm, vascular invasion, and incomplete tumor excision were significant adverse prognostic factors. Tumor grade and histology did not affect patient outcome. In conclusion, pleomorphic liposarcoma is a rare, often deep-seated and limb-based aggressive and metastasizing neoplasm of late adulthood. It shows a wide range of morphologic appearances, but tumor grade and histology have no effect on patient outcome.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11979090     DOI: 10.1097/00000478-200205000-00006

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  47 in total

1.  [Isolated limb perfusion for liposarcoma : Histopathological response and subgroup analysis after TNF melphalan-based ILP].

Authors:  L E Podleska; B Schwindenhammer; F Grabellus; S Bauer; H-U Steinau; G Taeger
Journal:  Chirurg       Date:  2017-05       Impact factor: 0.955

2.  Occurrence of colonic liposarcoma after retroperitoneal liposarcoma.

Authors:  Jin Hwa Choi; In Gyu Hwang; Seong Jae Cha; Tae Jin Lee; Joung-Soon Jang
Journal:  Korean J Intern Med       Date:  2014-12-30       Impact factor: 2.884

Review 3.  The application of immunohistochemistry in the diagnosis of bone tumors and tumor-like lesions.

Authors:  Zhenqiang Gao; Leonard B Kahn
Journal:  Skeletal Radiol       Date:  2005-09-28       Impact factor: 2.199

Review 4.  Soft tissue sarcomas with complex genomic profiles.

Authors:  Louis Guillou; Alain Aurias
Journal:  Virchows Arch       Date:  2010-02       Impact factor: 4.064

Review 5.  [Pleomorphic high-grade soft tissue sarcomas: is the subclassification up to date?].

Authors:  G Mechtersheimer; M Renner; R Penzel; P Schirmacher
Journal:  Pathologe       Date:  2011-02       Impact factor: 1.011

6.  The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma.

Authors:  Fritz C Eilber; Frederick R Eilber; Jeffery Eckardt; Gerald Rosen; Elyn Riedel; Robert G Maki; Murray F Brennan; Samuel Singer
Journal:  Ann Surg       Date:  2004-10       Impact factor: 12.969

7.  [liposarcoma. Aspects of pathomorphology--an analysis of 209 tumos].

Authors:  C Kuhnen; M Lehnhardt; H U Steinau; K-M Müller
Journal:  Chirurg       Date:  2004-12       Impact factor: 0.955

8.  Added Value of Molecular Biological Analysis in Diagnosis and Clinical Management of Liposarcoma: A 30-Year Single-Institution Experience.

Authors:  Ronald S A de Vreeze; Daphne de Jong; Petra M Nederlof; Aafke Ariaens; Ivon H G Tielen; Luc Frenken; Rick L Haas; Frits van Coevorden
Journal:  Ann Surg Oncol       Date:  2010-03       Impact factor: 5.344

9.  Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma.

Authors:  Samuel Singer; Cristina R Antonescu; Elyn Riedel; Murray F Brennan
Journal:  Ann Surg       Date:  2003-09       Impact factor: 12.969

Review 10.  The histological variants of liposarcoma: predictive MRI findings with prognostic implications, management, follow-up, and differential diagnosis.

Authors:  Magda Rizer; Adam D Singer; Mark Edgar; Jean Jose; Ty K Subhawong
Journal:  Skeletal Radiol       Date:  2016-05-21       Impact factor: 2.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.